Talha Badar: Multi-Institutional Study on Outcomes in TP53-Mutated ALL
Talha Badar, Hematology/Oncology Specialist at Mayo Clinic, shared on X about a recent paper by Ethan J. Harris et al. published on Blood Cancer Journal:
“Happy to contribute to this multi-institutional study led by Caner Saygin on outcomes in TP53-mutated ALL.
Key findings:
- Overall survival (OS): Median OS < 2 years, regardless of B-cell or T-cell lineage.
- Treatment response: Blinatumomab (Blina) or inotuzumab ozogamicin (InO) yielded better responses than conventional chemotherapy, but the benefit was not durable.
- Cytogenetics: Frequently associated with hypodiploidy.
- Mutation status: No prognostic difference observed between monoallelic vs. biallelic TP53 mutations.”
Title: Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults
Authors: Ethan J. Harris, Diren Arda Karaoglu, Madina Sukhanova, Yasmin Abaza, Theodoros Karantanos, Ann-Kathrin Eisfeld, Clare Anderson, Chenyu Lin, Yenny A. Moreno Vanegas, Talha Badar, Alexander Coltoff, Todd C. Knepper, Neval Ozkaya, Hamed Rahmani Youshanlouei, Sinan Cetin, Anand A. Patel, Adam S. DuVall, Michael W. Drazer, Peng Wang, Melissa Tjota, Jeremy P. Segal, Girish Venkataraman, Sandeep Gurbuxani, Jason X. Cheng, Daniel A. Arber, Richard A. Larson, Olatoyosi Odenike, Jonathan Webster, Bijal Shah, Wendy Stock and Caner Saygin
More posts featuring Talha Badar.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023